June 29, 2021
Kissei Pharmaceutical said on June 28 that it has entered into a sublicense agreement with South Korea’s JW Pharmaceutical for the rights to develop and commercialize the spleen tyrosine kinase inhibitor fostamatinib in the country. Fostamatinib, an oral small molecule...read more